- 18 abstracts accepted, underscoring Alcon’s commitment to
vision, comfort and ocular surface health
- TOTAL30 designed with water gradient technology that has
biomimetic properties that mimic the corneal surface and
demonstrates exceptional comfort from day one to day 30
Regulatory News:
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will present new data on several
of its latest innovations at the British Contact Lens Association
(BCLA) 2021 Clinical Conference & Exhibition. Among the 18
Alcon abstracts accepted are data on TOTAL30®, which will be the
first and only monthly replacement water gradient contact lens.
“We are delighted to partner with the BCLA to present our robust
scientific data on several of our products, notably on TOTAL30,
which is designed to address two of the key factors to maximise
contact lens wearer retention: comfort and vision,” said Cheryl
Donnelly, International Head of Professional Affairs at Alcon.
“Whilst we will miss the in-person interaction, the virtual BCLA
event will enable us to share promising clinical evidence with even
more eye care professionals so they can make informed decisions
about patient care.”
Alcon at BCLA 2021 (June
13-14)
As the partner sponsor, Alcon will host:
- “Comfort in Practice” Powered by Alcon (Sunday, June 13 at 3
pm BST): Profs. Jennifer Craig, Lyndon Jones and Greg Sawyer,
moderated by Eric Papas, will highlight the link between the ocular
surface and contact lens materials. Discomfort is still the number
one reason for contact lens wearer dropout; however, research
suggests that biomimicry in contact lens materials may lead to
better wearing experiences.
- Sponsor Sessions (please consult full programme for dates
and times): “A lens to start in and stay in,” where Associate
Clinical Professor Kathy Dumbleton will be joined by Tim Grant, Dr.
Inma Perez and Dr. Rick Weisbarth to give a brief introduction to
PRECISION1TM; and, “Water Surface Contact Lenses” where Dr.
John Pruitt will summarise water surface technologies, highlighting
the differences and benefits for wearers.
- A virtual booth where attendees can explore Alcon’s
latest innovations, including the proprietary Alcon science behind
our innovations. The booth will be live on the BCLA 2021 event
website as of June 7.
TOTAL30 Monthly Replacement Contact
Lens Demonstrates Outstanding Wearing Experience
Following the success of DAILIES TOTAL1®, TOTAL30 will be the
first-and-only monthly replacement water gradient contact lens. The
lens features an innovative water gradient material with biomimetic
Celligent™ technology.
Alcon will present data from several studies of TOTAL30, which
evaluated the integrity of the material surface after on-eye wear,
durability during a full month of wear and daily cleaning,
disinfecting and storing, surface softness compared to other
contact lens materials, wettability after 30 days of on-eye wear,
and surface and structure properties.
Results from these studies demonstrate that TOTAL30 lenses
feature exceptional lubricity, outstanding surface softness and
high durability.
Alcon expects to introduce TOTAL30 contact lenses in the U.S.
and select markets in Europe in 2021. Broader commercial
availability worldwide is planned for 2022.
To learn more about the Alcon innovation to be presented at
BCLA, download the Alcon BCLA 2021 Abstract Book.
Eye care professionals: see instructions for use for contact
lens wear, care, precautions, warnings, contraindications and
adverse effects. Consumers should consult their eye care
professionals.
Cautionary Note Regarding
Forward-Looking Statements
This press release contains, and our officers and
representatives may from time to time make, certain
“forward-looking statements” within the meaning of the safe harbor
provisions of the US Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as
“anticipate,” “intend,” “commitment,” “look forward,” “maintain,”
“plan,” “goal,” “seek,” “target,” “assume,” “believe,” “project,”
“estimate,” “expect,” “strategy,” “future,” “likely,” “may,”
“should,” “will” and similar references to future periods. Examples
of forward-looking statements include, among others, statements
Alcon makes regarding its liquidity, revenue, gross margin,
effective tax rate, foreign currency exchange movements, earnings
per share, its plans and decisions relating to various capital
expenditures, capital allocation priorities and other discretionary
items, market growth assumptions, and generally, its expectations
concerning its future performance and the effects of the COVID-19
pandemic on its businesses.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
Alcon’s current beliefs, expectations and assumptions regarding the
future of its business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict such as: the effect of the COVID-19
pandemic as well as other viral or disease outbreaks and the
availability of vaccines; the commercial success of its products
and its ability to maintain and strengthen its position in its
markets; the success of its research and development efforts,
including its ability to innovate to compete effectively; its
success in completing and integrating strategic acquisitions; its
ability to successfully transition the manufacture, distribution
and commercialization of Simbrinza from Novartis; its ability to
leverage existing relationships with healthcare professionals to
help drive patient adoption of Simbrinza; pricing pressure from
changes in third party payor coverage and reimbursement
methodologies; global and regional economic, financial, legal, tax,
political, and social change; data breaches or other disruptions of
its information technology systems; ongoing industry consolidation;
its ability to properly educate and train healthcare providers on
its products; changes in inventory levels or buying patterns of its
customers; the impact of a disruption in its global supply chain or
important facilities; ability to service its debt obligations; its
ability to comply with the US Foreign Corrupt Practices Act of 1977
and other applicable anti-corruption laws, particularly given that
it has entered into a three-year Deferred Prosecution Agreement
with the US Department of Justice; uncertainty and impact relating
to the potential phasing out of LIBOR and transition to alternative
reference rates; the need for additional financing through the
issuance of debt or equity; its reliance on outsourcing key
business functions; its ability to protect its intellectual
property; the impact of unauthorized importation of its products
from countries with lower prices to countries with higher prices;
uncertainties regarding the success of Alcon’s separation and
Spin-off from Novartis and the subsequent transformation program,
including the expected separation and transformation costs, as well
as any potential savings, incurred or realized by Alcon; the
effects of litigation, including product liability lawsuits and
government investigations; its ability to comply with all laws to
which it may be subject; effect of product recalls or voluntary
market withdrawals; the implementation of its enterprise resource
planning system; its ability to attract and retain qualified
personnel; the accuracy of its accounting estimates and
assumptions, including pension plan obligations and the carrying
value of intangible assets; the ability to obtain regulatory
clearance and approval of its products as well as compliance with
any post-approval obligations, including quality control of its
manufacturing; legislative and regulatory reform; the ability of
Alcon Pharmaceuticals Ltd. to comply with its investment tax
incentive agreement with the Swiss State Secretariat for Economic
Affairs in Switzerland and the Canton of Fribourg, Switzerland; its
ability to manage environmental, social and governance matters to
the satisfaction of its many stakeholders, some of which may have
competing interests; its ability to operate as a stand-alone
company; whether the transitional services Novartis has agreed to
provide Alcon are sufficient; the impact of the spin-off from
Novartis on Alcon’s shareholder base; the impact of being listed on
two stock exchanges; the ability to declare and pay dividends; the
different rights afforded to its shareholders as a Swiss
corporation compared to a US corporation; and the effect of
maintaining or losing its foreign private issuer status under US
securities laws. Additional factors are discussed in Alcon’s
filings with the United States Securities and Exchange Commission,
including its Form 20-F. Should one or more of these uncertainties
or risks materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those
anticipated. Therefore, you should not rely on any of these
forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and Alcon assumes no obligation to
update forward-looking statements as a result of new information,
future events or otherwise.
ABOUT ALCON
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning more than seven decades, we offer the
broadest portfolio of products to enhance sight and improve
people’s lives. Our Surgical and Vision Care products touch the
lives of more than 260 million people in over 140 countries each
year living with conditions like cataracts, glaucoma, retinal
diseases and refractive errors. Our more than 23,000 associates are
enhancing the quality of life through innovative products,
partnerships with eye care professionals and programs that advance
access to quality eye care. Learn more at www.alcon.com.
Reference
- Rumpakis JMB. New data on contact lens dropouts: an
international perspective. Rev Optometry. January 15,
2010:1-4.
Connect with us on Facebook LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210607005742/en/
Investor Relations Christina
Cheng + 41 589 112 110 (Geneva) + 1 817 615 2789 (Fort Worth)
investor.relations@alcon.com
Media Relations Steven Smith
+ 41 589 112 111 (Geneva) + 1 817 551 8057 (Fort Worth)
globalmedia.relations@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Jul 2023 to Jul 2024